Not for the treatment of dementia-related psychosis. Increased prevalence of diabetes in patients w/ schizophrenia. Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia & weakness. Prostatic hypertrophy or paralytic ileus & related conditions. Not recommended in the treatment of dopamine agonist associated psychosis in patients w/ parkinson's disease. Patients w/ elevated ALT &/or AST, signs & symptoms of hepatic impairment, preexisting conditions associated w/ limited hepatic functional reserve & in patients who are being treated w/ potentially hepatotoxic drugs. Discontinue treatment if hepatitis occurs. Patients w/ low leukocyte &/or neutrophil counts, history of drug-induced bone marrow depression/toxicity, patients receiving medicines known to cause neutropenia, bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy, hypereosinophilic conditions or w/ myeloproliferative disease, elderly patients w/ dementia-related psychosis. Discontinue if neuroleptic malignant syndrome occurs. History of seizures or risk factors which may lower seizure threshold. Discontinue or reduce dose if tardive dyskinesia occurs. Combination w/ other centrally-acting drugs & alcohol; drugs known to increase QTc interval especially in the elderly, patients w/ congenital long QT syndrome, CHF, heart hypertrophy, hypokalemia, hypomagnesaemia. Renal &/or hepatic impairment. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr.